Skip to content

Homeopathic medicines in irritable bowel syndrome

Double-blind, randomized, placebo-controlled, feasibility trial of individualized homeopathic medicines in irritable bowel syndrome

Status
Recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/03/031710
Enrollment
50
Registered
2021-03-04
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K580- Irritable bowel syndrome with diarrhea

Interventions

Intervention1: Individualized homeopathic medicines: It is planned as administering indicated homeopathic remedies in centesimal potencies, as decided appropriate to the case or condition. All medicin
dosage and repetition depending upon the individual requirement of the cases. Route of administration: Oral. Patients will be given general advices to avoid foods which trigger the disease condition l

Sponsors

D N De Homoeopathic Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients suffering from IBS (ICD-10-CM K58.0) as per Rome IV diagnostic criteria 2. Age 18-65 years 3. Patients of either sex 4. Patients who are literate and capable of filling the questionnaire and providing written informed consent

Exclusion criteria

Exclusion criteria: 1. Patients who are too unwell to take part 2. Inability to read patient information sheets and/or denied consent to take part 3. Diagnosed cases of unstable psychiatric complaints or other systemic diseases affecting quality of life 4. Any major gastro-intestinal surgery in last 6 months 5. Currently receiving standard therapy for IBS and/or homoeopathic treatment for any chronic condition(s) 6. Pregnant, puerperial and lactating women 7. Self-reported immune compromised conditions 8. Substance abuse and/or dependence

Design outcomes

Primary

MeasureTime frame
IBS Quality of Life (IBS-QOL) questionnaire total and individual domain scoresTimepoint: At baseline and after 2 months

Secondary

MeasureTime frame
IBS symptom severity scores (IBS-SSS)Timepoint: At baseline and after 2 months

Countries

India

Contacts

Public ContactShifa Hashmi

D. N. De Homoeopathic Medical College and Hospital

shyamalmukhergee@gmail.com9831113383

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026